MD3628331T2 - Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic - Google Patents

Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic Download PDF

Info

Publication number
MD3628331T2
MD3628331T2 MDE20200898T MDE20200898T MD3628331T2 MD 3628331 T2 MD3628331 T2 MD 3628331T2 MD E20200898 T MDE20200898 T MD E20200898T MD E20200898 T MDE20200898 T MD E20200898T MD 3628331 T2 MD3628331 T2 MD 3628331T2
Authority
MD
Moldova
Prior art keywords
particles
micronized
microns
alpha
lactose monohydrate
Prior art date
Application number
MDE20200898T
Other languages
English (en)
Romanian (ro)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3628331(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MD3628331T2 publication Critical patent/MD3628331T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
MDE20200898T 2015-11-16 2016-11-14 Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic MD3628331T2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194660 2015-11-16

Publications (1)

Publication Number Publication Date
MD3628331T2 true MD3628331T2 (ro) 2021-12-31

Family

ID=54548062

Family Applications (3)

Application Number Title Priority Date Filing Date
MDE20200898T MD3628331T2 (ro) 2015-11-16 2016-11-14 Procedeu de preparare unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic
MDE20180917T MD3377108T2 (ro) 2015-11-16 2016-11-14 Procedeu de obţinere a unei formulări de pulbere uscată ce conţine un anticolinergic, un corticosteroid și un beta-adrenergic
MDE20200899T MD3620176T2 (ro) 2015-11-16 2016-11-14 Procedeu pentru prepararea unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic

Family Applications After (2)

Application Number Title Priority Date Filing Date
MDE20180917T MD3377108T2 (ro) 2015-11-16 2016-11-14 Procedeu de obţinere a unei formulări de pulbere uscată ce conţine un anticolinergic, un corticosteroid și un beta-adrenergic
MDE20200899T MD3620176T2 (ro) 2015-11-16 2016-11-14 Procedeu pentru prepararea unei formulări sub formă de pulbere uscată care cuprinde un anticolinergic, un corticosteroid și un beta-adrenergic

Country Status (36)

Country Link
US (4) US10086004B2 (enExample)
EP (3) EP3628331B1 (enExample)
JP (1) JP6963548B2 (enExample)
KR (1) KR20180082443A (enExample)
CN (1) CN108289962B (enExample)
AR (1) AR106688A1 (enExample)
AU (1) AU2016356858B2 (enExample)
CA (1) CA3005290A1 (enExample)
CL (1) CL2018001298A1 (enExample)
CO (1) CO2018005141A2 (enExample)
CY (3) CY1123042T1 (enExample)
DK (3) DK3377108T3 (enExample)
EA (1) EA037716B1 (enExample)
ES (3) ES2891073T3 (enExample)
GE (1) GEP20207157B (enExample)
HR (3) HRP20211598T1 (enExample)
HU (3) HUE049751T2 (enExample)
IL (1) IL259329B (enExample)
LT (3) LT3620176T (enExample)
MA (3) MA50487B1 (enExample)
MD (3) MD3628331T2 (enExample)
ME (1) ME03778B (enExample)
MX (1) MX379853B (enExample)
MY (1) MY186229A (enExample)
PE (1) PE20181488A1 (enExample)
PH (1) PH12018501022B1 (enExample)
PL (3) PL3620176T3 (enExample)
PT (3) PT3628331T (enExample)
RS (3) RS60171B1 (enExample)
SA (1) SA518391570B1 (enExample)
SG (2) SG10201912093YA (enExample)
SI (3) SI3377108T1 (enExample)
TW (1) TWI731891B (enExample)
UA (1) UA125019C2 (enExample)
WO (1) WO2017085004A1 (enExample)
ZA (1) ZA201803168B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48620A (fr) 2017-05-11 2021-04-28 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MX379783B (es) * 2017-05-11 2025-03-04 Chiesi Farm Spa Proceso para preparar una formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico.
US11433063B1 (en) 2019-03-12 2022-09-06 Belhaven Biopharma, Inc. Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides
WO2020198716A1 (en) * 2019-03-27 2020-10-01 Kemin Industries, Inc. Methods for preparing metal carboxylates in one-pot reaction
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12178782B2 (en) * 2021-03-24 2024-12-31 Cmpd Licensing, Llc Drug powderization within vials
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
ATE503517T2 (de) 2002-07-31 2011-04-15 Chiesi Farma Spa Pulverinhalator
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
PH12012502404A1 (en) * 2010-06-22 2013-02-18 Chiesi Farm Spa Dry powder formulation comprising an antimuscarinic drug
MX369311B (es) * 2012-12-06 2019-11-05 Chiesi Farm Spa Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
AR093832A1 (es) * 2012-12-06 2015-06-24 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
BR112015030914B1 (pt) * 2013-07-11 2023-04-04 Chiesi Farmaceutici S.P.A Formulação de pó seco

Also Published As

Publication number Publication date
MA50488B1 (fr) 2021-09-30
US20200368252A1 (en) 2020-11-26
MA50487B1 (fr) 2021-09-30
GEP20207157B (en) 2020-10-12
US10966991B2 (en) 2021-04-06
JP2019501876A (ja) 2019-01-24
NZ742474A (en) 2024-11-29
UA125019C2 (uk) 2021-12-29
CY1124475T1 (el) 2022-07-22
EA037716B1 (ru) 2021-05-13
JP6963548B2 (ja) 2021-11-10
MA43256A (fr) 2018-09-26
SI3620176T1 (sl) 2021-11-30
BR112018009807A2 (pt) 2018-11-06
RS62404B1 (sr) 2021-10-29
PE20181488A1 (es) 2018-09-18
EP3377108A1 (en) 2018-09-26
HUE049751T2 (hu) 2020-10-28
PL3620176T3 (pl) 2021-11-22
ES2891073T3 (es) 2022-01-26
PH12018501022A1 (en) 2018-12-17
MA50487A (fr) 2021-04-28
IL259329A (en) 2018-07-31
EP3377108B1 (en) 2020-02-19
CY1124490T1 (el) 2022-07-22
PL3377108T3 (pl) 2020-09-07
US10772896B2 (en) 2020-09-15
ES2895687T3 (es) 2022-02-22
DK3377108T3 (da) 2020-04-20
ZA201803168B (en) 2019-07-31
BR112018009807A8 (pt) 2019-02-26
MA50488A (fr) 2021-05-19
PL3628331T3 (pl) 2021-11-08
EP3628331A1 (en) 2020-04-01
HUE056441T2 (hu) 2022-02-28
PT3628331T (pt) 2021-10-20
ME03778B (me) 2021-04-20
MA43256B1 (fr) 2020-05-29
CO2018005141A2 (es) 2018-09-28
CL2018001298A1 (es) 2018-09-14
MD3377108T2 (ro) 2020-07-31
US11628175B2 (en) 2023-04-18
AU2016356858A1 (en) 2018-05-31
DK3620176T3 (da) 2021-09-20
CN108289962B (zh) 2021-09-14
MX379853B (es) 2025-03-11
HRP20211600T1 (hr) 2022-01-21
US10086004B2 (en) 2018-10-02
DK3628331T3 (da) 2021-09-27
AU2016356858B2 (en) 2021-06-24
HRP20200537T1 (hr) 2020-06-26
LT3620176T (lt) 2021-11-10
MD3620176T2 (ro) 2021-12-31
HRP20211598T1 (hr) 2022-01-07
SG10201912093YA (en) 2020-02-27
TWI731891B (zh) 2021-07-01
CA3005290A1 (en) 2017-05-26
EP3620176B1 (en) 2021-08-11
SG11201804050QA (en) 2018-06-28
PT3620176T (pt) 2021-09-28
SI3377108T1 (sl) 2020-05-29
RS62506B1 (sr) 2021-11-30
WO2017085004A1 (en) 2017-05-26
HUE056260T2 (hu) 2022-02-28
EP3620176A1 (en) 2020-03-11
US20170136035A1 (en) 2017-05-18
LT3628331T (lt) 2021-11-10
PT3377108T (pt) 2020-04-08
SI3628331T1 (sl) 2021-11-30
CN108289962A (zh) 2018-07-17
KR20180082443A (ko) 2018-07-18
CY1123042T1 (el) 2021-10-29
ES2783855T3 (es) 2020-09-18
LT3377108T (lt) 2020-07-10
MX2018005977A (es) 2018-08-29
TW201722404A (zh) 2017-07-01
RS60171B1 (sr) 2020-05-29
US20210177866A1 (en) 2021-06-17
MY186229A (en) 2021-06-30
US20180360849A1 (en) 2018-12-20
EA201890966A1 (ru) 2018-11-30
IL259329B (en) 2020-10-29
AR106688A1 (es) 2018-02-07
PH12018501022B1 (en) 2018-12-17
EP3628331B1 (en) 2021-08-11
SA518391570B1 (ar) 2022-03-27

Similar Documents

Publication Publication Date Title
US11628175B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US10959944B2 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
BR112018009807B1 (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
HK1255959A1 (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
HK1255959B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
HK1256859B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic